Business & Finance

Johnson & Johnson to buy Momenta for about $6.5bn

  • J&J will pay $52.50 for each Momenta share, a 70.4pc premium to Tuesday's closing price.
Published Updated
By

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.

J&J will pay $52.50 for each Momenta share, a 70.4pc premium to Tuesday's closing price.